

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the Hong Kong prospectus dated December 30, 2025 (the “**Prospectus**”) of Shenzhen Edge Medical Co., Ltd. (深圳市精鋒醫療科技股份有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.

In connection with the Global Offering, Morgan Stanley Asia Limited as stabilizing manager (the “**Stabilization Manager**”) (or its affiliates or any person acting for it), on behalf of the Underwriters, the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at such price, in such amounts and in such manners as the Stabilization Manager, its affiliates or any person acting for it may determine and at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or its affiliates or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of our Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering. Such Stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Potential investors should be aware that no stabilizing action can be taken to support the price of the H Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to term and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Sponsors and Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. on the Listing Date (which is currently expected to be on Thursday, January 8, 2026).



Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 27,722,200 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	: 2,772,300 H Shares
Number of International Offer Shares	: 24,949,900 H Shares (subject to the Over-allotment Option)
Offer Price	: HK\$43.24 per H Share, plus brokerage of 1.0%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.00565%
Nominal value	: RMB1.00 per H Share
Stock code	: 2675

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*

Morgan Stanley



*Overall Coordinators, Joint Global Coordinators Joint Bookrunners
and Joint Lead Managers*



Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager



Shenzhen Edge Medical Co., Ltd.
深圳市精鋒醫療科技股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 30, 2025 (the “**Prospectus**”) issued by Shenzhen Edge Medical Co., Ltd. (the “**Company**”).*

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded and should exercise extreme caution when dealing in the Shares.	
SUMMARY	
Company information	
Stock code	2675
Stock short name	EDGE MEDICAL-B
Dealings commencement date	January 8, 2026*
* see note at the end of the announcement	
Price Information	
Final Offer Price	HK\$43.24
Offer Price Adjustment exercised	N/A
Offer Shares and Share Capital	
Number of Offer Shares	27,722,200
Number of Offer Shares in Hong Kong Public Offering	2,772,300
Number of Offer Shares in International Offering	24,949,900
Number of issued Shares upon Listing	387,722,200
Over-allocation	
No. of Offer Shares over-allocated	4,158,300
<i>Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange’s website.</i>	

Proceeds	
Gross proceeds (Note)	HK\$1,198.7 million
Less: Estimated listing expenses payable based on Final Offer Price	HK\$(82.1) million
Net proceeds	HK\$1,116.6 million
<i>Note: Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus. The Company intends to apply the additional net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed “Future Plans and Use of Proceeds” of the Prospectus on a pro rata basis. During the Track Record Period, the Company incurred HK\$20.2 million of listing expenses, among which, HK\$18.5 million was charged to the consolidated statements of profit or loss of the Company.</i>	

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	196,179
No. of successful applications	19,967
Subscription level	1,091.94 times
Claw-back triggered	No
No. of Offer Shares initially available under the Hong Kong Public Offering	2,772,300
% of Offer Shares under the Hong Kong Public Offering to the Global Offering	10%
Final no. of Offer Shares under the Hong Kong Public Offering (after over-allocation)	2,772,300
% of final no. of Offer Shares under the Hong Kong Public Offering to the Global Offering (after over-allocation)	8.70%

Note: For details of the final allocation of Shares to the Hong Kong Public Offering, investors can refer to <http://www.hkeipo.hk/IPOResult> to perform a search by identification number or <http://www.tricor.com.hk/ipo/result> for the full list of allottees.

INTERNATIONAL OFFERING

No. of places	175
Subscription Level	25.18 times
No. of Offer Shares initially available under the International Offering	24,949,900
% of Offer Shares under the International Offering to the Global Offering	90%
Final no. of Offer Shares under the International Offering (after over-allocation)	29,108,200
% of final no. of Offer Shares under the International Offering to the Global Offering (after over-allocation)	91.30%

The Directors confirm that, to the best of their knowledge, information and belief, save for consent to permit the Company to, among other things, allocate Shares in the International Offering to certain existing Shareholders and close associates of certain existing Shareholders, (i) none of the Offer Shares subscribed by the places and the public have been financed directly or indirectly by the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the places and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, Supervisors, chief executive of the Company, controlling shareholders, substantial shareholders, existing shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The places in the International Offering include the following:

Cornerstone Investors

<i>Investor</i> ^{Note 1}	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 2}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 2}	<i>Existing Shareholders or their close associates</i>
Abu Dhabi Investment Authority	2,699,000	9.74%	0.70%	No
UBS Asset Management (Singapore) Ltd. ^{Note 3}	1,799,300	6.49%	0.46%	No
OrbiMed Genesis Master Fund, L.P. ^{Note 4}	1,799,300	6.49%	0.46%	Existing Shareholder
Huang River Investment Limited	899,600	3.25%	0.23%	No
LYFE Capital Fund IV (Dragon), L.P. ^{Note 5}	899,600	3.25%	0.23%	Close associate of an existing shareholder

<i>Investor</i> ^{Note 1}	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 2}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 2}	<i>Existing Shareholders or their close associates</i>
Poly Platinum Enterprises Limited ^{Note 6}	539,800	1.95%	0.14%	Close associate of an existing shareholder
Mega Prime Development Limited ^{Note 6}	359,800	1.30%	0.09%	Close associate of an existing shareholder
China Asset Management (Hong Kong) Limited ^{Note 7}	899,600	3.25%	0.23%	No
China Alpha Fund Management (HK) Ltd	899,600	3.25%	0.23%	No
Tekful Limited	539,800	1.95%	0.14%	No
Integrated Core Strategies (Asia) Pte. Ltd.	539,800	1.95%	0.14%	No
Sage Partners Master Fund ^{Note 8}	539,800	1.95%	0.14%	Close associate of an existing shareholder
Panjing Harbourview Investment Fund	539,800	1.95%	0.14%	No
Infini Global Master Fund	539,800	1.95%	0.14%	No
Total	13,494,600	48.68%	3.48%	

Note:

1. For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.
2. Before any exercise of the Over-allotment Option.
3. UBS Asset Management (Singapore) Ltd. (“**UBS AM Singapore**”) is a connected client of UBS AG Singapore Branch (“**UBS AG Singapore**”). For details of consent under paragraph 1C(1) of Appendix F1 of the Listing Rules (the “**Placing Guidelines**”) in relation to allocations to connected clients as Cornerstone Investors, please refer to the section headed “Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained” in this announcement.
4. OrbiMed Genesis Master Fund, L.P. (“**OrbiMed Genesis**”) and its close associate, OrbiMed New Horizons Master Fund, L.P., are existing Shareholders of our Company, holding in aggregate approximately 0.33% of the equity interest in the Company immediately prior to the Global Offering. For details of consent under Rule 10.04 and paragraph 1C(2) of the Placing Guidelines for allocation of Offer Shares to a close associate of an existing shareholder as Cornerstone Investor, please refer to the section headed “Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained” in this announcement.

<i>Investor</i> ^{Note 1}	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 2}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 2}	<i>Existing Shareholders or their close associates</i>
5.	<i>LYFE Capital Fund IV (Dragon), L.P. is a close associate of Guadalupe Peak Limited, which in turn holds approximately 5.27% equity interest in the Company immediately prior to the Global Offering. For details of consent under paragraph 1C(2) of the Placing Guidelines for allocation of Offer Shares to a close associate of an existing shareholder as Cornerstone Investor, please refer to the section headed “Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained” in this announcement.</i>			
6.	<i>Mega Prime Development Limited and Poly Platinum Enterprises Limited are close associates of GBA Fund Investment Limited (“GBA Fund”), with GBA Fund holding approximately 0.33% of the equity interest in the Company immediately prior to the Global Offering. For details of consent under paragraph 1C(2) of the Placing Guidelines for allocation of Offer Shares to a close associate of an existing shareholder as Cornerstone Investor, please refer to the section headed “Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained” in this announcement.</i>			
7.	<i>China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)”) is a connected client of CLSA Limited. For details of consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients as Cornerstone Investors, please refer to the section headed “Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained” in this announcement.</i>			
8.	<i>Sage Partners Master Fund is a close associate of Sage Partners Alpha 1 L.P. (“Sage Partners”) with Sage Partners holding approximately 0.20% of the equity interest in the Company immediately prior to the Global Offering. For details of consent under paragraph 1C(2) of the Placing Guidelines for allocation Offer Shares to a close associate of an existing shareholder as Cornerstone Investor, please refer to the section headed “Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained” in this announcement.</i>			

Allottees with Waivers/Consents Obtained

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 1}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 1}	<i>Relationship</i>
<i>Allottees with consent under Rule 10.04 of the Listing Rules and/or Paragraph 1C(2) of the Placing Guidelines – Allocation of Offer Shares to an existing shareholder and/or close associates of existing shareholders</i> ^{Note 2}				
OrbiMed Genesis	1,799,300	6.49%	0.46%	A Cornerstone Investor, an existing shareholder and a close associate of an existing shareholder
LYFE Capital Fund IV (Dragon), L.P.	899,600	3.25%	0.23%	A Cornerstone Investor and a close associate of an existing shareholder
Poly Platinum Enterprises Limited	539,800	1.95%	0.14%	A Cornerstone Investor and a close associate of an existing shareholder

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 1}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 1}	<i>Relationship</i>
Mega Prime Development Limited	359,800	1.30%	0.09%	A Cornerstone Investor and a close associate of an existing shareholder
Sage Partners Master Fund	539,800	1.95%	0.14%	A Cornerstone Investor and a close associate of an existing shareholder
3H Health Investment Fund II, L.P.	540,000	1.95%	0.14%	A placee and a close associate of existing shareholders
Dragon Warrior Investments Limited	90,000	0.32%	0.02%	A placee and a close associate of existing shareholders
GF Securities Asset Management (Guangdong) Co., Ltd. (“ GF Securities AM ”)	1,800	0.01%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage Limited (“ GF Securities (Hong Kong) Brokerage ”) and a close associate of an existing shareholder
GF International Investment Management Limited (“ GF International ”),	1,800	0.01%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
E Fund Management Co., Ltd. (“ E Fund ”)	98,800	0.36%	0.03%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 1}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 1}	<i>Relationship</i>
E Fund Management (Hong Kong) Co., Ltd. (“E Fund Hong Kong”)	9,200	0.03%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
Value Partners Hong Kong Limited (“Value Partners”)	5,000	0.02%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
Taibai Investments Pte. Ltd.	900,000	3.25%	0.23%	A placee and a close associate of existing shareholders
Mirae Asset Securities Co., Ltd.	3,500	0.01%	0.00%	A placee and a close associate of an existing shareholder
Mirae Asset Securities (HK) Limited	90,000	0.32%	0.02%	A placee and a close associate of an existing shareholder
CICC Financial Trading Limited	6,500	0.02%	0.00%	A placee, a connected client of China International Capital Corporation Hong Kong Securities Limited (“CICCHKS”) and a close associate of an existing shareholder

Note:

- Before any exercise of the Over-allotment Option.*
- For details of the consent under Rule 10.04 of the Listing Rules and paragraph 1C(2) of the Placing Guidelines granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the International Offering to existing shareholders and/or close associates of existing Shareholders, please refer to the section headed “Waivers and Exemption” in the Prospectus and the section headed “Others/Additional Information” in this announcement.*

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 1}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 1}	<i>Relationship</i>
<i>Allottees with consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients</i> ^{Note 2}				
ChinaAMC (HK)	899,600	3.25%	0.23%	A Cornerstone Investor and a connected client of CLSA Limited (“CLSA”)
GF International Investment Management Limited (“GF International”)	1,800	0.01%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
GF Securities Asset Management (Guangdong) Co., Ltd. (“GF Securities AM”)	1,800	0.01%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>Approximate % of Offer Shares</i> ^{Note 1}	<i>Approximate % of total issued share capital after the Global Offering</i> ^{Note 1}	<i>Relationship</i>
E Fund Management Co., Ltd. (“E Fund”)	98,800	0.36%	0.03%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
E Fund Management (Hong Kong) Limited (“E Fund Hong Kong”)	9,200	0.03%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
Value Partners Hong Kong Limited (“Value Partners”)	5,000	0.02%	0.00%	A placee, a connected client of GF Securities (Hong Kong) Brokerage and a close associate of an existing shareholder
UBS Asset Management (Singapore) Ltd. (“UBS AM Singapore”)	1,799,300	6.49%	0.46%	A placee and a connected client of UBS AG Singapore Branch (“UBS AG Singapore”)
ICBC UBS Asset Management Co., Ltd. (“ICBC UBS”)	125,000	0.45%	0.03%	A placee and a connected client of UBS AG Singapore
CICC Financial Trading Limited (“CICC FT”)	6,500	0.02%	0.00%	A placee, a connected client of CICCHKS and a close associate of an existing shareholder
CITIC Securities International Capital Management Limited (“CSICM”)	741,400	2.67%	0.19%	A placee and a connected client of CLSA
<p><i>Note:</i></p> <p>1. Before any exercise of the Over-allotment Option.</p> <p>2. For details of the consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to the section headed “Waivers and Exemption” in the Prospectus and the section headed “Others/Additional Information” in this announcement.</p>				

LOCK-UP UNDERTAKINGS

Controlling Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i> ^{Note 1}	<i>Last day subject to the lock-up undertakings</i>
Dr. Wang ^{Note 2}	31,368,798 Unlisted Shares 73,193,861 H Shares	26.97%	January 8, 2027 ^{Note 3}
Dr. Gao ^{Note 2}	15,500,065 Unlisted Shares 36,166,819 H Shares	13.33%	January 8, 2027 ^{Note 3}
Xieli Chuangfeng ^{Note 2}	10,708,126 H Shares	2.76%	January 8, 2027 ^{Note 3}
Subtotal	166,937,669	43.06%	
<p><i>Notes:</i></p> <p>(1) Before any exercise of the Over-allotment Option.</p> <p>(2) Dr. Wang is the sole general partner of Xieli Chuangfeng. By virtue of their spousal relationship, Dr. Wang and Dr. Gao, together with Xieli Chuangfeng (an entity controlled by Dr. Wang) form a group of Controlling Shareholders of our Company upon Listing.</p> <p>(3) The expiry day of the lock-up period shown in the table above is pursuant to the PRC Company Law. In accordance with the relevant Listing Rule and guidance materials, the required lock-up for the First Six-Month Period ends on July 8, 2026 and the Second Six-Month Period ends on January 8, 2027.</p>			

Pre-IPO Investors

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i> ^{Note 1}	<i>Last day subject to the lock-up undertakings</i>
Chengdu Mingsheng	17,504,640 H Shares	4.51%	January 8, 2027 ^{Note 2}
Zhongheng Huijin	16,359,120 H Shares	4.22%	January 8, 2027 ^{Note 2}
Suzhou Junlian	701,778 Unlisted Shares 11,787,990 H Shares	3.22%	January 8, 2027 ^{Note 2}
Sanzheng Zhengyun	11,691,424 H Shares	3.02%	January 8, 2027 ^{Note 2}
Social Security Fund	272,913 Unlisted Shares 4,584,216 H Shares	1.25%	January 8, 2027 ^{Note 2}

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i> ^{Note 1}	<i>Last day subject to the lock-up undertakings</i>
Shenzhen Zhihui	4,473,922 H Shares	1.15%	January 8, 2027 ^{Note 2}
Khorgos Lianpan	4,892,760 H Shares	1.26%	January 8, 2027 ^{Note 2}
Beijing Xinghao	4,892,760 H Shares	1.26%	January 8, 2027 ^{Note 2}
HongShan Growth	1,290,060 Unlisted Shares 3,010,140 H Shares	1.11%	January 8, 2027 ^{Note 2}
Taijiashan Healthcare Fund	1,318,189 Unlisted Shares 3,075,775 H Shares	1.13%	January 8, 2027 ^{Note 2}
Shenzhen Hanchen	1,318,189 Unlisted Shares 3,075,775 H Shares	1.13%	January 8, 2027 ^{Note 2}
Guoce Green Technology	3,998,261 H Shares	1.03%	January 8, 2027 ^{Note 2}
Guoce Technology Manufacturing	2,817,275 H Shares	0.73%	January 8, 2027 ^{Note 2}
Jiaying Siqu	333,586 H Shares	0.09%	January 8, 2027 ^{Note 2}
Jiaying Yusheng	168,360 H Shares	0.04%	January 8, 2027 ^{Note 2}
Lingang Lanwan Fund I	2,388,960 H Shares	0.62%	January 8, 2027 ^{Note 2}
China State-owned Enterprise Mixed Ownership Reform Fund	1,911,240 H Shares	0.49%	January 8, 2027 ^{Note 2}
Vertex Investment	441,270 Unlisted Shares 1,323,810 H Shares	0.46%	January 8, 2027 ^{Note 2}
Beijing Yahui Jinlin	1,715,040 H Shares	0.44%	January 8, 2027 ^{Note 2}
Yu Anding (余安定)	1,476,720 H Shares	0.38%	January 8, 2027 ^{Note 2}
Hainan Yuanfeng	1,466,280 H Shares	0.38%	January 8, 2027 ^{Note 2}
Hangzhou Kangyin	1,466,280 H Shares	0.38%	January 8, 2027 ^{Note 2}
CICC Pucheng	1,466,280 H Shares	0.38%	January 8, 2027 ^{Note 2}
Chengdu Boyuan Jiayu	1,466,280 H Shares	0.38%	January 8, 2027 ^{Note 2}
Wuxi FirstLight	1,194,480 H Shares	0.31%	January 8, 2027 ^{Note 2}
Guangyuan Zhonghe	1,168,560 H Shares	0.30%	January 8, 2027 ^{Note 2}
Jiaying Suizi	944,216 H Shares	0.24%	January 8, 2027 ^{Note 2}
Fan Xiaolin (范曉霖)	716,760 H Shares	0.18%	January 8, 2027 ^{Note 2}

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i> ^{Note 1}	<i>Last day subject to the lock-up undertakings</i>
Qingdao Yizhou	716,760 H Shares	0.18%	January 8, 2027 ^{Note 2}
Hangzhou Xiangshu	477,720 H Shares	0.12%	January 8, 2027 ^{Note 2}
Guangzhou Jinyuan	422,071 H Shares	0.11%	January 8, 2027 ^{Note 2}
Jiang Hao (姜昊)	372,960 H Shares	0.10%	January 8, 2027 ^{Note 2}
Guadalupe Peak Limited	4,741,110 Unlisted Shares 14,223,330 H Shares	4.89%	January 8, 2027 ^{Note 2}
Intelligent Spark	4,300,128 Unlisted Shares 10,033,632 H Shares	3.70%	January 8, 2027 ^{Note 2}
Spark Plug	2,388,960 H Shares	0.62%	January 8, 2027 ^{Note 2}
Robust Edge Investments	10,563,551 H Shares	2.72%	January 8, 2027 ^{Note 2}
Centroid Investments	8,386,920 H Shares	2.16%	January 8, 2027 ^{Note 2}
Springleaf Investments	2,293,380 Unlisted Shares 5,351,220 H Shares	1.97%	January 8, 2027 ^{Note 2}
True Light	573,372 Unlisted Shares 1,337,868 H Shares	0.49%	January 8, 2027 ^{Note 2}
Kangji Medical	5,865,840 H Shares	1.51%	January 8, 2027 ^{Note 2}
GBA Fund	1,194,480 H Shares	0.31%	January 8, 2027 ^{Note 2}
Sage Partners	716,760 H Shares	0.18%	January 8, 2027 ^{Note 2}
Octagon Investments	716,760 H Shares	0.18%	January 8, 2027 ^{Note 2}
OrbiMed Genesis	597,240 H Shares	0.15%	January 8, 2027 ^{Note 2}
OrbiMed New Horizons	597,240 H Shares	0.15%	January 8, 2027 ^{Note 2}
Mirae Asset Global Investments	477,720 H Shares	0.12%	January 8, 2027 ^{Note 2}
Subtotal	193,062,331	49.79%	
<i>Notes:</i>			
(1) Before any exercise of the Over-allotment Option.			
(2) The expiry day of the lock-up period shown in the table above is pursuant to the PRC Company Law.			

Cornerstone Investors

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i> ^{Note 1}	<i>Last day subject to the lock-up undertakings</i>
Abu Dhabi Investment Authority	2,699,000	0.70%	July 8, 2026 ^{Note 2}
UBS Asset Management (Singapore) Ltd.	1,799,300	0.46%	July 8, 2026 ^{Note 2}
OrbiMed Genesis Master Fund, L.P.	1,799,300	0.46%	July 8, 2026 ^{Note 2}
Huang River Investment Limited	899,600	0.23%	July 8, 2026 ^{Note 2}
China Asset Management (Hong Kong) Limited	899,600	0.23%	July 8, 2026 ^{Note 2}
LYFE Capital Fund IV (Dragon), L.P.	899,600	0.23%	July 8, 2026 ^{Note 2}
Poly Platinum Enterprises Limited	539,800	0.14%	July 8, 2026 ^{Note 2}
Mega Prime Development Limited	359,800	0.09%	July 8, 2026 ^{Note 2}
China Alpha Fund Management (HK) Ltd	899,600	0.23%	July 8, 2026 ^{Note 2}
Tekful Limited	539,800	0.14%	July 8, 2026 ^{Note 2}
Integrated Core Strategies (Asia) Pte. Ltd.	539,800	0.14%	July 8, 2026 ^{Note 2}
Sage Partners Master Fund	539,800	0.14%	July 8, 2026 ^{Note 2}
Panjing Harbourview Investment Fund	539,800	0.14%	July 8, 2026 ^{Note 2}
Infini Global Master Fund	539,800	0.14%	July 8, 2026 ^{Note 2}
Total	13,494,600	3.48%	
<p><i>Notes:</i></p> <p>(1) Before any exercise of the Over-allotment Option.</p> <p>(2) The expiry day of the lock-up period shown in the table above is pursuant to the relevant Cornerstone Investment Agreements.</p>			

Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over- allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming the Over- allotment Option is fully exercised and new H Shares are issued)
2,699,000	10.8%	9.3%	8.5%
8,963,600	35.9%	30.8%	28.1%
13,462,400	54.0%	46.2%	42.2%
22,392,700	89.8%	76.9%	70.2%

* *Ranking of placees is based on the number of Shares allotted to the placees.*

H SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing as % of total issued H share capital upon Listing (assuming no exercise of the Over-allotment Option)	Number of H Shares held upon Listing as % of total issued H share capital upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of Shares held upon Listing
Top 1	–	0.0%	0.0%	0.0%	37.1%	36.6%	166,937,669
Top 5	746,600	3.0%	2.6%	2.7%	62.7%	61.9%	250,705,381
Top 10	2,546,200	10.2%	8.7%	9.2%	78.6%	77.6%	318,168,229
Top 25	11,515,900	46.2%	39.6%	41.5%	92.5%	91.3%	362,994,613

Note:

* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholder upon Listing.

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised and new Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new Shares are issued)	Number of Shares held upon Listing	Number of Shares held upon Listing as % of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	Number of Shares held upon Listing as % of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised and new Shares are issued)
Top 1	-	0.0%	0.0%	0.0%	0.0%	166,937,669	43.1%	42.6%
Top 5	1,646,200	6.6%	5.7%	5.9%	5.2%	253,222,524	65.3%	64.6%
Top 10	2,546,200	10.2%	8.7%	9.2%	8.0%	318,168,229	82.1%	81.2%
Top 25	11,515,900	46.2%	39.6%	41.5%	36.1%	363,293,413	93.7%	92.7%

Note:

* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, 19,967 valid applications made by the public will be conditionally allocated on the basis set out below:

Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot POOL A	Approximate % allotted of the total no. of H Shares applied for
100	91,082	456 out of 91,082 applicants to receive 100 H Shares	0.50%
200	28,073	242 out of 28,073 applicants to receive 100 H Shares	0.43%
300	3,955	47 out of 3,955 applicants to receive 100 H Shares	0.40%
400	1,934	29 out of 1,934 applicants to receive 100 H Shares	0.37%
500	2,746	49 out of 2,746 applicants to receive 100 H Shares	0.36%
600	1,206	25 out of 1,206 applicants to receive 100 H Shares	0.35%
700	957	22 out of 957 applicants to receive 100 H Shares	0.33%
800	1,046	27 out of 1,046 applicants to receive 100 H Shares	0.32%
900	771	22 out of 771 applicants to receive 100 H Shares	0.32%
1,000	17,714	532 out of 17,714 applicants to receive 100 H Shares	0.30%
1,500	2,607	108 out of 2,607 applicants to receive 100 H Shares	0.28%
2,000	4,622	238 out of 4,622 applicants to receive 100 H Shares	0.26%
2,500	2,431	149 out of 2,431 applicants to receive 100 H Shares	0.25%
3,000	1,627	115 out of 1,627 applicants to receive 100 H Shares	0.24%
3,500	894	72 out of 894 applicants to receive 100 H Shares	0.23%
4,000	1,004	89 out of 1,004 applicants to receive 100 H Shares	0.22%
4,500	811	79 out of 811 applicants to receive 100 H Shares	0.22%
5,000	1,853	195 out of 1,853 applicants to receive 100 H Shares	0.21%
6,000	1,167	142 out of 1,167 applicants to receive 100 H Shares	0.20%
7,000	947	130 out of 947 applicants to receive 100 H Shares	0.20%

Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot POOL A	Approximate % allotted of the total no. of H Shares applied for
8,000	872	132 out of 872 applicants to receive 100 H Shares	0.19%
9,000	686	114 out of 686 applicants to receive 100 H Shares	0.18%
10,000	5,686	1,024 out of 5,686 applicants to receive 100 H Shares	0.18%
20,000	3,901	1,205 out of 3,901 applicants to receive 100 H Shares	0.15%
30,000	2,405	1,019 out of 2,405 applicants to receive 100 H Shares	0.14%
40,000	1,268	672 out of 1,268 applicants to receive 100 H Shares	0.13%
50,000	1,324	835 out of 1,324 applicants to receive 100 H Shares	0.13%
60,000	797	579 out of 797 applicants to receive 100 H Shares	0.12%
70,000	686	562 out of 686 applicants to receive 100 H Shares	0.12%
80,000	557	507 out of 557 applicants to receive 100 H Shares	0.11%
90,000	455	100 H Shares	0.11%
100,000	3,693	100 H Shares plus 297 out of 3,693 applicants to receive an additional 100 H Shares	0.11%
Total	189,777	Total number of Pool A successful applicants: 13,565	

Number of H Shares applied for	Number of valid applications	Basis of allocation/ballot POOL B	Approximate % allotted of the total no. of H Shares applied for
200,000	4,438	100 H Shares plus 3,551 out of 4,438 applicants to receive an additional 100 H Shares	0.09%
300,000	769	200 H Shares plus 165 out of 769 applicants to receive an additional 100 H Shares	0.07%
400,000	315	200 H Shares plus 178 out of 315 applicants to receive an additional 100 H Shares	0.06%
500,000	209	200 H Shares plus 183 out of 209 applicants to receive an additional 100 H Shares	0.06%
600,000	113	300 H Shares	0.05%
700,000	85	300 H Shares plus 26 out of 85 applicants to receive an additional 100 H Shares	0.05%
800,000	66	300 H Shares plus 45 out of 66 applicants to receive an additional 100 H Shares	0.05%
900,000	30	300 H Shares plus 25 out of 30 applicants to receive an additional 100 H Shares	0.04%
1,000,000	92	400 H Shares	0.04%
1,386,100	285	400 H Shares plus 274 out of 285 applicants to receive an additional 100 H Shares	0.04%
Total	6,402	Total number of Pool B successful applicants: 6,402	

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHER INFORMATION

Consent under Rule 10.04 and/or paragraph 1C(2) of the Placing Guidelines – Allocation of Offer Shares to an existing shareholder and/or close associates of existing shareholders as cornerstone investors

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, consent under Rule 10.04 of the Listing Rules Paragraph 1C(2) of the Placing Guidelines for the allocation of Offer Shares to (i) OrbiMed Genesis, (ii) Mega Prime Development Limited and Poly Platinum Enterprises Limited, (iii) LYFE Capital Fund IV (Dragon), L.P. and (iv) Sage Partners Master Fund as Cornerstone Investors under the Global Offering. Please refer to the section headed “Waivers and Exemption – Waiver and consent under Rule 10.04 and Paragraph 1C(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer Shares by existing shareholder and close associates of existing shareholder as cornerstone investors” in the Prospectus for details.

Consent under paragraph 1C(2) of the Placing Guidelines – Allocation of Offer Shares to close associates of existing shareholders as placees

The Company has applied to the Stock Exchange, and the Stock Exchange has granted a consent under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the close associates of existing shareholders as placees (together, the “**Close Associates of Existing Shareholders as Placees**”). Each of 3H Health Investment Fund II, L.P. and Dragon Warrior Investments Limited is a close associate of Robust Edge Investments Limited and Centroid Investments Limited. Each of GF Securities AM, GF International, E Fund, E Fund Hong Kong and Value Partners is a close associate of Guangfa Xinde Zhongheng Huijin (Longyan) Equity Investment Partnership (Limited Partnership) (廣發信德中恒匯金(龍岩)股權投資合夥企業(有限合夥)). Taibai Investments Pte. Ltd. is a close associate of Springleaf Investments Pte. Ltd. and True Light Investments Pte. Ltd.. Each of Mirae Asset Securities Co., Ltd. and Mirae Asset Securities (HK) Limited is a close associate of Mirae Asset Global Investments (Hong Kong) Limited. CICC FT is a close associate of CICC Pucheng Investment Co., Ltd. (中金浦成投資有限公司). The allocation of Offer Shares to the Close Associates of Existing Shareholders as Placees is in compliance with all the conditions under the consent granted by the Stock Exchange, including but not limited to (i) the Company complies with Rules 19A.13A and 19A.13C of the Listing Rules, and (ii) no preference in allocation was given to the Close Associates of Existing Shareholders as Placees.

For details of the allocations of Offer Shares to close associates of existing Shareholders, please refer to the section headed “Allotment Results Details — International Offering — Allotees with Waivers/Consents Obtained” in this announcement.

Placing to connected clients with prior consents under paragraph 1C(1) of the Placing Guidelines

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, consents under paragraph 1C(1) of the Placing Guidelines to permit allocation to connected clients pursuant to the Placing Guidelines. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consents granted by the Stock Exchange. Details of the placement to connected clients in placing tranche are set out below.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted a consent under paragraph 1C(1) of the Placing Guidelines to permit ChinaAMC (HK) to participate in the Global Offering as a Cornerstone Investor and connected client holding the Offer Shares on a discretionary basis. Please refer to the section headed “Waivers and Exemption – Consent in respect of the proposed subscription of Offer Shares by Connected Client” in the Prospectus for details.

In addition, the Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to connected clients. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consent granted by the Stock Exchange. Details of the placement to the connected clients are set out below.

No.	Name of connected client	Name of connected distributor	Relationship with the connected distributor	Basis of holding securities	Number of Offer Shares subscribed	Approximate percentage of the Offer Shares subscribed (assuming the Over-allotment Option is not exercised)	Approximate percentage of total issued share capital after the Global Offering (assuming no exercise of the Over-allotment Option)
1.	GF International ⁽¹⁾ (as placee)	GF Securities (Hong Kong) Brokerage, one of the Overall Coordinators	GF International is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	1,800	0.01%	0.00%
2.	GF Securities AM ⁽²⁾ (as placee)	GF Securities (Hong Kong) Brokerage, one of the Overall Coordinators	GF Securities AM is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Non-discretionary	1,800	0.01%	0.00%
3.	E Fund ⁽³⁾ (as placee)	GF Securities (Hong Kong) Brokerage, one of the Overall Coordinators	E Fund is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	98,800	0.36%	0.03%
4.	E Fund Hong Kong ⁽⁴⁾ (as placee)	GF Securities (Hong Kong) Brokerage, one of the Overall Coordinators	E Fund Hong Kong is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	9,200	0.03%	0.00%
5.	Value Partners ⁽⁵⁾ (as placee)	GF Securities (Hong Kong) Brokerage, one of the Overall Coordinators	Value Partners is a member of the same group of companies as GF Securities (Hong Kong) Brokerage.	Discretionary	5,000	0.02%	0.00%

<i>No.</i>	<i>Name of connected client</i>	<i>Name of connected distributor</i>	<i>Relationship with the connected distributor</i>	<i>Basis of holding securities</i>	<i>Number of Offer Shares subscribed</i>	<i>Approximate percentage of the Offer Shares subscribed (assuming the Over-allotment Option is not exercised)</i>	<i>Approximate percentage of total issued share capital after the Global Offering (assuming no exercise of the Over-allotment Option)</i>
6.	UBS AM Singapore ⁽⁶⁾ (as cornerstone investor)	UBS AG Singapore, one of the distributors of the Global Offering	UBS AM Singapore is a member of the same group of companies as UBS AG Singapore.	Discretionary	1,799,300	6.49%	0.46%
7.	ICBC UBS ⁽⁷⁾ (as placee)	UBS AG Singapore, one of the distributors of the Global Offering	ICBC UBS is a member of the same group of companies as UBS AG Singapore.	Discretionary	125,000	0.45%	0.03%
8.	CICC FT ⁽⁸⁾ (as placee)	CICCHKS, one of the Overall Coordinators	CICC FT is a member of the same group of companies as CICCHKS.	Non-discretionary	6,500	0.02%	0.00%
9.	CSICM ⁽⁹⁾ (as placee)	CLSA, one of the Overall Coordinators	CSICM is a member of the same group of companies as CLSA.	Non-discretionary	Shenzhen Commando: 741,400 36,000 Beevest: 700,000 Perseverance AM: 5,400	Shenzhen Commando: 2.67% 0.13% Beevest: 2.53% Perseverance AM: 0.02%	Shenzhen Commando: 0.19% 0.01% Beevest: 0.18% Perseverance AM: 0.00%

Notes:

- (1) GF International will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of their underlying clients (the “**GF International Ultimate Clients**”), each of which is an independent third party. Save for Ku Sen (顧晨), none of the GF International Ultimate Clients holds 30% or more ultimate beneficial interest in the relevant funds. GF International has confirmed that, to the best of their knowledge, each of the GF International Ultimate Clients is an independent party of GF International, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage.
- (2) GF Securities AM is an asset manager that is a QDII as approved by the relevant authority and will hold the Offer Shares as product manager on behalf of GF Asset Management Excellent Diversified Allocation No. 10 (QDII) Single Asset Management Plan (廣發資產卓越多元配置 10 號(QDII)單一資產管理計劃), with the ultimate client being Feng Tianhong (馮倩紅) (the “**GF Securities AM Ultimate Client**”). GF Securities AM has confirmed that, to the best of their knowledge, the GF Securities AM Ultimate Client is an independent party of GF Securities AM, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage.

- (3) E Fund will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of their underlying clients (the “**E Fund Ultimate Clients**”), each of which is an independent third party. None of the E Fund Ultimate Clients holds more than 30% ultimate beneficial interest in the relevant funds. E Fund has confirmed that, to the best of their knowledge, each of the E Fund Ultimate Clients is an independent party of E Fund, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage.
- (4) E Fund Hong Kong will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of their underlying clients (the “**E Fund Hong Kong Ultimate Clients**”), each of which is an independent third party. None of the E Fund Hong Kong Ultimate Clients holds more than 30% ultimate beneficial interest in the relevant funds. E Fund Hong Kong has confirmed that, to the best of their knowledge, each of the E Fund Hong Kong Ultimate Clients is an independent party of E Fund Hong Kong, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage.
- (5) Value Partners will hold the Offer Shares in its capacity as the discretionary fund manager managing the SFC-authorized funds on behalf of their underlying clients (the “**Value Partners Ultimate Clients**”), each of which is an independent third party. The ultimate beneficial owners holding 30% or more interest in the SFC-authorized collective authorized schemes are set out below:
- (i) AIA International Limited
 - (ii) Bank of China (Hong Kong) Nominees Limited
 - (iii) The Master Trust Bank of Japan Limited.

Value Partners has confirmed that, to the best of their knowledge, each of the Value Partners Ultimate Clients is an independent party of Value Partners, GF Securities (Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities (Hong Kong) Brokerage.

- (6) UBS AM Singapore will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors (the “**UBS AM Singapore Ultimate Clients**”), each of which is an independent third party. None of the UBS AM Singapore Ultimate Clients holds more than 30% ultimate beneficial interest in the relevant funds. UBS AM Singapore has confirmed that, to the best of their knowledge, each of the UBS AM Singapore Ultimate Clients is an independent party of UBS AM Singapore, UBS AG Singapore and the companies which are members of the same group of companies as UBS AG.
- (7) ICBC UBS will hold the Offer Shares in its capacity as the discretionary fund manager managing the funds on behalf of their investors (the “**ICBC UBS Ultimate Clients**”), each of which is an independent third party. None of the ICBC UBS Ultimate Clients holds more than 30% ultimate beneficial interest in the relevant funds. ICBC UBS has confirmed that, to the best of their knowledge, each of the ICBC UBS Ultimate Clients is an independent party of ICBC UBS, UBS AG Singapore and the companies which are members of the same group of companies as UBS AG.

- (8) CICC FT and China International Capital Corporation Limited will enter into a series of cross border delta-one OTC swap transactions (collectively, the “**CICC OTC Swaps**”) with each other and the ultimate client (the “**CICC FT Ultimate Client**”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary basis to hedge the CICC OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICC FT Ultimate Client, subject to customary fees and commissions. The CICC OTC Swaps will be fully funded by the CICC FT Ultimate Client. During the terms of the CICC OTC Swaps, all economic returns of the Offer Shares subscribed by CICC FT will be passed to the CICC FT Ultimate Client and all economic loss shall be borne by the CICC FT Ultimate Client through the CICC OTC Swaps, and CICC FT will not take part in any economic return or bear any economic loss in relation to the Offer Shares. Despite that CICC FT will hold the legal title of the Offer Shares by itself, it will not exercise the voting rights attaching to the relevant Offer Shares during the terms of the CICC OTC Swaps according to its internal policy. The CICC FT Ultimate Client is Shanghai Baoyin Private Equity Fund Management Co., Ltd. (上海保銀私募基金管理有限公司) (“**Pinpoint Fund**”), which in turn manages the funds Baoyin Duokong Wenjian No. 1 Private Equity Investment Fund (保銀多空穩健1號私募證券投資基金) (“**Duokong Wenjian No. 1**”), Baoyin Duokong Wenjian No. 2 Private Equity Investment Fund (保銀多空穩健2號私募證券投資基金) (“**Duokong Wenjian No. 2**”) and Baoyin Jinqu No. 1 Private Equity Investment Fund (保銀進取1號私募證券投資基金) (“**Jinqu No. 1**”). The ultimate beneficial owner holding 30% or more interest in Duokong Wenjian No. 1 and Duokong Wenjian No. 2 is. Wang Qiang (王強), with no other ultimate beneficial owners holding 30% or more interest in Duokong Wenjian No.1, Duokong Wenjian No. 2 and Jinqu No.1. To the best of CICC FT’s knowledge, after making all reasonable inquiries, each of the CICC FT Ultimate Client and its ultimate beneficial owner is a third party independent from CICC FT and CICCHKS and the companies which are members of the same group of companies as CICCHKS.
- (9) CSICM will act as the single counterparty of a back-to-back total return swap transaction (the “**CSICM Back-to-back TRS**”) to be entered into by CSICM in connection with a total return swap order (the “**CSICM Client TRS**”) placed by its ultimate clients (the “**CSICM Ultimate Clients**”), by which CSICM will pass the full economic exposure of the Offer Shares placed to CSICM (the “**CSICM Offer Shares**”) to the CSICM Ultimate Client, meaning in effect, CSICM will hold the beneficial interest of the CSICM Offer Shares on behalf of the CSICM Ultimate Clients on a non-discretionary basis. CSICM will hold the legal title and beneficial interest in the CSICM Offer Shares, but will contractually agree to pass on the full economic exposure and return of the CSICM Offer Shares to the CSICM Ultimate Clients. The CSICM Ultimate Clients may exercise an early termination right to early terminate the CSICM Client TRS at any time from the trade date of the CSICM Client TRS which should be on or after the date on which the CSICM Offer Shares are listed on the Stock Exchange. Upon the final maturity or early termination of the CSICM Client TRS by the CSICM Ultimate Clients, CSICM will dispose of the CSICM Offer Shares on the secondary market and the CSICM Ultimate Clients will receive a final termination amount of the CSICM Back-to-back TRS which should have taken into account all the economic returns or economic loss in relation to the CSICM Offer Shares and the fixed amount of transaction fees of the CSICM Back-to back TRS and the CSICM Client TRS. CSICM will not exercise the voting right of the CSICM Offer Shares during the tenor of the CSICM Back-to-back TRS. The CSICM Ultimate Clients are (i) Shenzhen Commando Capital Management Co., Ltd. (深圳市康曼德資本管理有限公司) investing for and on behalf of nine different funds in the PRC, with the ultimate beneficial owners holding 30% or more interest in such funds being Ding Ying (丁楹), Huang Xiaolei (黃曉蕾) and Guo Hongqi (郭紅奇), with no other persons holding 30% or more interests therein; and (ii) Beevest Capital Management Limited, investing for and on behalf of Global Multi Alpha Fund SP, with the ultimate beneficial owner holding 30% or more interest in such fund being Zeng Shuzhen and (iii) Perseverance Asset Management L.L.p. (上海高毅資產管理合夥企業(有限合夥)), investing for and on behalf of five different funds in the PRC, with no ultimate beneficial owners holding 30% or more interest in such funds. To the best of CSICM’s knowledge, after making all reasonable inquiries, each of the CSICM Ultimate Clients and its ultimate beneficial owner is a third party independent from CSICM, CLSA and the companies which are members of the same group of companies as CLSA

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated December 30, 2025 issued by Shenzhen Edge Medical Co., Ltd. for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Thursday, January 8, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Immediately after the completion of the Global Offering, 191,842,718 H Shares, representing approximately 49.48% of the issued share capital of our Company (before any exercise of the Over-allotment Option) will count towards the public float. Therefore, the number of H shares held in public hands is higher than the prescribed percentage of H Shares required to be held in public hands of 15% under Rule 19A.13A(1) of the Listing Rules, satisfying the minimum percentage requirement in compliance with Rule 19A.13A(1) of the Listing Rules calculated based on the Offer Price of HK\$43.24 per Offer Share.

Each of the Cornerstone Investors has agreed to a lock-up period of six months following the Listing Date. As such, Shares held by the Cornerstone Investors upon the Listing shall not be counted towards the free float of the Shares of the Company at the time of Listing. Based on the final Offer Price of HK\$43.24 per H Share, the Company satisfies the free float requirement under Rule 19A.13C(1)(b) of the Listing Rules.

The Directors confirm that, immediately following completion of the Global Offering: (i) the Shares will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule 8.08(2) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than 50% of the H Shares held in public hands at the time of Listing, in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; (iii) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; and (iv) there will not be any new substantial Shareholder (as defined in the Listing Rules) immediately after the Global Offering.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time) on Thursday, January 8, 2026, provided that (i) the Global Offering has become unconditional in all respects, and (ii) the right of termination described in the section headed “Underwriting – Underwriting Arrangements and Expenses – Hong Kong Underwriting Agreement – Grounds for termination” in the Prospectus has not been exercised. Investors who trade H Shares prior to the receipt of H Share certificates or the H Share certificates becoming valid evidence of title do so entirely at their own risk. Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time) on Thursday, January 8, 2026, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Thursday, January 8, 2026. The H Shares will be traded in board lots of 100 H Shares each and the stock code of the H Shares will be 2675.

By order of the Board
Shenzhen Edge Medical Co., Ltd.
(深圳市精鋒醫療科技股份有限公司)
Dr. Wang Jianchen
Chairman of the Board and Executive Director

Hong Kong, January 7, 2026

As of the date of this announcement, the board of directors of the Company comprises (i) Dr. Wang Jianchen, Dr. Gao Yuanqian and Ms. Wu Mengyuan as executive directors; (ii) Mr. Sheng Li, Mr. Chen Gang and Mr. Qiu Xiang as non-executive directors, and (iii) Mr. Yang Fan, Mr. Zhang Guoguang and Mr. Lau Ying Kit as independent non-executive directors.